SpinalCyte receives additional patents: 3 takeaways

Written by Mackenzie Garrity | November 08, 2018 | Print  |

Regenerative medicine company SpinalCyte was issued new patents in Hong Kong and Europe.

Here are three takeaways:

1. The patents are for its lead product CybroCell, an off-the-shelf allogenic human dermal fibroblast product to treat degenerative disc disease.

2. Throughout several clinical trials, CybroCell demonstrated improved pain relief and increased back mobility in patients treated with the fibroblast.

3. SpinalCyte has 35 U.S. and foreign patents issued and 41 patents pending.

More articles on biologics:
3 things to know about Lattice Biologics' CEO
Cellect receives patent approval for Apograft technology: 3 notes
OsteoRemedies unveils 1st FDA-cleared dual-antibiotic spacer & bone cement: 3 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months